Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon therapy

Journal of Medical Virology

Volumn 59, Issue 2, 1999, Pages 146-153

  Lu, Mengji ^a   Wiese, Manfred ^b   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Klinikum St Georg   (Germany)

Author keywords

HCV; Selection by tFN ; Variants

Indexed keywords

ALPHA INTERFERON;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; VIRUS GENE; VIRUS REPLICATION;

5' UNTRANSLATED REGIONS; ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA, VIRAL; VARIATION (GENETICS); VIRUS REPLICATION;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0032856089     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199910)59:2<146::AID-JMV4>3.0.CO;2-O     Document Type: Article

References (45)

1. Aiyama T, Yoshioka K, Hirofuji H, Kusakabe A, Yamada M, Tanaka K, Kakumu S. 1994. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 39:2244-2249.
2. Brown EA, Zhang H, Ping LH, Lemon SM. 1992. Secondary structure of the 5′ nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 20:5041-5045.
3. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.
4. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, Belussi F, Martinelli S, Alberti A. 1996. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Ann Intern Med 124:1058-1060.
5. Di Besceglie AM, Martin P, Kassianides C. 1989. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. N Engl J Med 321:1506-1510.
6. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. 1994. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 75:1361-1369.
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230.
8. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81.
9. Fried M, Hoofnagle J. 1995. Therapy of hepatitis C. Semin Liver Dis 15:82-91.
10. Fukushi S, Katayama K, Kurihara C, Ishiyama N, Hoshino RB, Ando T, Oya A. 1994. Complete 5′ noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. Biochem Biophys Res Commun 199:425-432.
11. Gale Jr. MJ, Blakely CM, Kwieciszewski B, Tan S-L, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. 1998. Control of PKR protein kinase by hepatitis virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18: 5208-5218.
12. Gale Jr. MJ, Korth MJ, Tang NM, Tan S-L, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
13. Gonzalez-Peralta RP, Liu WZ, Davis GL, Qian KP, Lau JY. 1997. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. J Viral Hepat 4:99-106.
14. Hagashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito S, Ishikawa T, Takayanagi M, Nagai Y. 1993. Dynamic of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 197:659-668.
15. Hershey JWB. 1989. Protein phosphorylation controls translation rates. J Biol Chem 264:20823-20826.
16. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. 1995. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 40:14-20.
17. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, Mayumi M. 1994. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 42:299-305.
18. Hoofnagle JH. 1994. Therapy of acute and chronic viral hepatitis. Adv Intern Med 39:241-275.
19. Iino S, Hino K, Yasuda K. 1994. Current state of interferon therapy for chronic hepatitis C. Intervirology 37:87-100.
20. Kanai K, Kako M, Okamoto H. 1992. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543.
21. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528.
22. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, Capron D, Capron JP, Lunel F, Stuyver L, Duverlie G. 1997. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 27:72-77.
23. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kievnan TW, Wollman J. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
24. Kohara M, Tanaka T, Tsukiyama Kohara K, Tanaka S, Mizokami M, Lau JY, Hattori N. 1995. Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologie kinetics. J Infect Dis 172:934-938.
25. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. 1993a. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-1504.
26. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. 1993b. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 342:1208-1209.
27. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. 1997. Hepatitis C virus genome complexitiy correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 25:1250-1254.
28. Lu M, Funsch B, Wiese M, Roggendorf M. 1995. Analysis of hepatitis C virus quasispecies population by temperature gradient gel electrophoresis. J Gen Virol 76:881-887.
29. Lu M, Wiese M, Funsch B, Roggendorf M. 1997. Different susceptibilities of genetic variants of hepatitis C virus (HCV) to interferon (IFN). Arch Virol 142:581-588.
30. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225-3229.
31. Meurs EF, Chong KL, Galabru J, Thomas N, Kerr I, Williams BRG, Hovanessian AG. 1990. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379-390.
32. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T. 1994. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 39:977-982.
33. Mizokami M, Lau JY, Suzuki K, Nakano T, Gojobori T. 1994. Differential sensitivity of hepatitis C virus quasispecies to interferon-alpha therapy. J Hepatol 21:884-886.
34. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
35. Polyak SJ, McArdle S, Liu S-L, Sullivan DG, Chung M, Hofgärtner WT, Carithers Jr. RL, McMahon BJ, Mullins JI, Corey L, Gretch DR. 1998. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 72:4288-4296.
36. Rispeter K, Lu M, Zibert A, de Oliveira J, Roggendorf M. 1998. Interferon sensitivity determining region is a stable genetic element. J Hepatol 29:352-361.
37. Sakuma I, Enomoto N, Kurosaki M, Marumo F, Sato C. 1996. Selection of hepatitis C virus quasispecies during interferon treatment. Arch Virol 141:1921-1932.
38. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
39. Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea MS, Yap PL, Simmonds P. 1995. Variation of the hepatitis C virus 5′ non-coding region: implication for secondary structure, virus detection and typing. J Gen Virol 76:1749-1761.
40. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. 1994. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094.
41. Wang C, Sarnow P, Siddiqui A. 1994. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. J Virol 68:7301-7307.
42. Yamamoto C, Enomoto N, Kurosaki M, Yu SH, Tazawa J, Izumi N, Marumo F, Sato C. 1997. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels. Hepatology 26:1616-1620.
43. Yeh BI, Han HK, Oh SH, Kim HS, Hong SH, Kin YS. 1996. Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-alpha therapy. J Med Virol 49:95-102.
44. Yun ZB, Odeberg J, Lundeberg J, Weiland O, Uhlen M, Sonnerborg A. 1996. Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load. J Infect Dis 173:992-996.
45. Zeuzem S, Lee JH, Roth WK. 1997. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25:740-744.